Yield10 Bioscience, Inc. (NASDAQ:YTEN) was the target of a large decrease in short interest in the month of March. As of March 31st, there was short interest totalling 29,400 shares, a decrease of 30.5% from the March 15th total of 42,300 shares. Based on an average daily trading volume, of 258,600 shares, the short-interest ratio is presently 0.1 days. Approximately 0.8% of the shares of the company are short sold.
In other news, major shareholder Jack W. Schuler acquired 101,400 shares of the firm’s stock in a transaction that occurred on Wednesday, February 3rd. The stock was acquired at an average cost of $12.25 per share, with a total value of $1,242,150.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 1.90% of the stock is currently owned by corporate insiders.
An institutional investor recently raised its position in Yield10 Bioscience stock. Cannell Peter B & Co. Inc. lifted its holdings in shares of Yield10 Bioscience, Inc. (NASDAQ:YTEN) by 55.3% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 144,625 shares of the specialty chemicals company’s stock after acquiring an additional 51,500 shares during the period. Cannell Peter B & Co. Inc. owned approximately 3.14% of Yield10 Bioscience worth $836,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 6.08% of the company’s stock.
NASDAQ:YTEN opened at $9.11 on Friday. The company has a 50-day moving average of $13.45 and a 200-day moving average of $10.26. The company has a market capitalization of $44.32 million, a price-to-earnings ratio of -0.42 and a beta of 2.17. Yield10 Bioscience has a 52 week low of $4.11 and a 52 week high of $23.49.
Yield10 Bioscience (NASDAQ:YTEN) last released its quarterly earnings data on Monday, March 15th. The specialty chemicals company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). Yield10 Bioscience had a negative return on equity of 347.89% and a negative net margin of 1,861.39%. As a group, equities research analysts predict that Yield10 Bioscience will post -4.78 earnings per share for the current fiscal year.
Yield10 Bioscience Company Profile
Yield10 Bioscience, Inc, an agricultural bioscience company, engages in developing disruptive technologies for step-changing improvements in crop yield in the United States and Canada. The company, through its Trait Factory, is involved in developing high value seed traits for the agriculture and food industries.
Featured Article: What are economic reports?
Receive News & Ratings for Yield10 Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yield10 Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.